abstract |
The present invention relates to processes for the identification of compounds and pharmaceutical compositions capable of selectively and potently inhibiting KDR/FLK-1 tyrosine kinase signal tranduction in order to inhibit vasculogenesis and/or angiogenesis. The present invention further relates to compounds and compositions identified using the methods of the invention and the use thereof for the treatment of disease relating to inappropriate vasculogenesis and/or angiogenesis. |